NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - NICE TAG TA472

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - NICE TAG TA472

1.1Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed.

https://www.nice.org.uk/guidance/ta472

Site by Devopa
© Copyright 2020 NHS. All rights reserved.